Drugs Targeting B-Cells in Autoimmune Diseases

Inbunden, Engelska, 2013

Av Xavier Bosch, Manuel Ramos-Casals, Munther A Khamashta

2 169 kr

Beställningsvara. Skickas inom 10-15 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

This book provides a detailed overview of B-cell directed therapies in patients with rheumatic and systemic autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome, ANCA-associated vasculitis and cryoglobulinemia. Organ-specific autoimmune diseases are discussed with respect to the use of B-cell directed therapies in neurological autoimmune diseases and autoimmune cytopenias. Situations in which B-cell targeted therapy may be indicated are identified, thereby offering comprehensive support for therapeutic decisions on the basis of the latest published evidence. The book also offers a valuable reference tool for rheumatologists, internists, nephrologists, immunologists, and all specialists involved in the multidisciplinary care of patients with rheumatic and systemic autoimmune diseases.

Produktinformation

Utgivningsdatum2013-12-09
Mått155 x 235 x 22 mm
Vikt623 g
FormatInbunden
SpråkEngelska
SerieMilestones in Drug Therapy
Antal sidor292
Upplaga2014
FörlagSpringer Basel
ISBN9783034807050

Tillhör följande kategorier

Historic outline of the development of drugs targeting B-cells.- Understanding B-cell biology.- Pharmacological effects and mechanisms of action of agents blocking B cells.- Systemic lupus erythematosus: direct B-cell blocking.- Systemic lupus erythematosus: indirect B-cell blocking.- B-cell targeted therapies in rheumatoid arthritis.- B-cell targeted therapies in Primary Sjögren Syndrome.- Targeting B cells in ANCA-associated vasculitis.- B-cell targeted therapies in systemic sclerosis and inflammatory myopathies.- B-cell targeted therapies in cryoglobulinemia.- B-cell targeted therapies in autoimmune cytopenias and thrombosis.- Targeting B cells in neurological autoimmune diseases.- Targeting B cells in other systemic autoimmune diseases.- Safety of B-cell targeted therapies.- The future potential of biosimilars targeting B-cells.